Source comparison
DAC vs Non-DAC: Binding Kinetics and Half-Life
CJC-1295 exists in two formulations: CJC-1295 DAC (with Drug Affinity Complex) and CJC-1295 no-DAC (also called modified GRF 1-29). The distinction is not trivial. It fundamentally alters the peptide's pharmacokinetics and dosing requirements. CJC-1295 DAC inc
This comparison does not assign a generated winner or score.
- CJC-1295 exists in two formulations: CJC-1295 DAC (with Drug Affinity Complex) and CJC-1295 no-DAC (also called modified GRF 1-29). The distinction is not trivial. It fundamentally alters the peptide's pharmacokinetics and dosing requirements.
- CJC-1295 DAC includes a lysine linker that allows the peptide to bind covalently to serum albumin, the most abundant plasma protein. This albumin binding dramatically extends half-life from minutes to days because albumin itself has a half-life of approximately 19 days in human circulation. The peptide remains bound to albumin in a reversible equilibrium, slowly dissociating and re-associating as it circulates. This creates a depot effect. A sustained-release mechanism without requiring depot injection formulations.
- The half-life of CJC-1295 DAC is approximately 6–8 days, meaning therapeutic plasma levels persist for 1–2 weeks after a single subcutaneous injection. This allows once- or twice-weekly dosing in research protocols. The trade-off is less controllability. Once administered, the peptide remains active for days, and there is no rapid washout if adverse effects occur.
- CJC-1295 no-DAC lacks the albumin-binding lysine modification. Its half-life is approximately 30 minutes. Longer than native GHRH (under 7 minutes) due to DPP-IV resistance, but still short enough to require multiple daily doses for sustained effect. The advantage is precise timing: researchers can dose CJC-1295 no-DAC before sleep to amplify the nocturnal GH surge, or pre-workout to capitalize on exercise-induced GH release, without extended systemic exposure.
- From a signaling pathway perspective, both variants bind the same GHRH receptor and activate the same Gs-cAMP-PKA-CREB cascade. The difference is duration of receptor occupancy, not mechanism. DAC provides prolonged low-level receptor stimulation; no-DAC provides intermittent high-level stimulation. Neither is inherently superior. The choice depends on research objectives and tolerance for continuous versus pulsatile signaling.